Endourethral Prosthesis is not intended for the treatment of strictures outside the bulbar urethra. The UroLume™ Endourethral Prosthesis is an alternative treatment for the patient in whom previous treatment methods (e.g., dilation, urethrotomy, or urethreplasty) have been unsuccessful (i.e., treatment was not effective initially in relieving stricture disease, or there has been recurrence of stricture formation necessitating further treatment).

On January 20, 1995, the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, reviewed and recommended approval of the application. On May 6, 1996, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH. A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH’s decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA’s administrative practices and procedures regulations or a review of the application and CDRH’s action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before November 8, 1996, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: September 20, 1996.

Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 96–25874 Filed 10–8–96; 8:45 am] BILLING CODE 4160–01–F

[Docket No. 96M–0358]

EDAP Technomed Group (U.S.A.), Inc.; Premarket Approval of Prostatron™

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by EDAP Technomed Group (U.S.A.), Inc., Cambridge, MA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the Prostatron™ device. After reviewing the recommendation of the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee, FDA’s Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of May 3, 1996, of the approval of the application.

DATES: Petitions for administrative review by November 8, 1996.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: John H. Baxley, Center for Devices and Radiological Health (HFZ–470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–2194.

SUPPLEMENTARY INFORMATION: On April 17, 1995, the EDAP Technomed Group submitted a petition (Docket No. 96M–0358) requesting premarket approval of the Prostatron™ device for the indication of benign prostatic hyperplasia (BPH) as an initial treatment for recurrent or severe obstructive symptoms. The device is intended for use in men to relieve voiding symptoms associated with recurrent or severe acute or chronic urinary retention that limits the patient’s daily life activities (BPH). The Prostatron™ device is an electromagnetic field therapy device intended to be used by or under the supervision of a health care practitioner. After reviewing the petition, FDA determined that additional safety and effectiveness data were needed. A summary of the safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (address above) are available from that office upon written request.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301±594±1195) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Centers for Devices and Radiological Health (21 CFR 5.53).

Dated: October 2, 1996.

Carolyn J. Russell,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 96–25874 Filed 10–8–96; 8:45 am] BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 96M–0356]

American Medical Systems, Inc.; Premarket Approval of UroLume™ Endourethral Prosthesis

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by American Medical Systems, Inc., Minnetonka, MN, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the UroLume™ Endourethral Prosthesis. After reviewing the recommendation of the Gastroenterology and Urology Devices Panel, FDA’s Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of May 6, 1996, of the approval of the application.

DATES: Petitions for administrative review by November 8, 1996.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: James P. Seiler, Center for Devices and Radiological Health (HFZ–470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–1195.

SUPPLEMENTARY INFORMATION: On June 14, 1993, American Medical Systems, Inc., Minnetonka, MN 55343, submitted to CDRH an application for premarket approval of the UroLume™ Endourethral Prosthesis. The device is intended for use in men to relieve urinary obstruction secondary to recurrent benign bulbar urethral strictures less than 3 centimeters in length located distal to the external sphincter and proximal to the bulbar scrotal junction. The UroLume™ Endourethral Prosthesis is not intended as an initial treatment for bulbar urethral strictures nor for the treatment of strictures outside the bulbar urethra. The UroLume™ Endourethral Prosthesis is an alternative treatment for the patient in whom previous treatment methods (e.g., dilation, urethrotomy, or urethreplasty) have been unsuccessful (i.e., treatment was not effective initially in relieving stricture disease, or there has been recurrence of stricture formation necessitating further treatment).

On January 20, 1995, the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, reviewed and recommended approval of the application. On May 6, 1996, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH. A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH’s decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA’s administrative practices and procedures regulations or a review of the application and CDRH’s action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before November 8, 1996, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. This notice is issued under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360e(d), 360(h)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: September 20, 1996.

Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 96–25874 Filed 10–8–96; 8:45 am] BILLING CODE 4160–01–F